RAPP
Rapport Therapeutics, Inc.BS score 58.8MEDIUMPHASE2 · mkt cap $1.64B · rev ttm $0
drug hypothesis
RAP-219 modulates Not specified in filing - target not disclosed to treat Refractory focal epilepsy (focal onset seizures).
moa:Not specified in filing - MOA not disclosed
score breakdown
trial design67
base rate disconnect40
language red flags80
composite58.8
valuation analysis
market cap$1.64B
revenue ttm$0
phasePHASE2
historical base rate8%
disconnect ratio1.4x
lead trialNCT07046494
meta
cik0002012593
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 2, non-randomized, single-arm, open-label, not placebo-controlled, N=30 adult participants with refractory focal epilepsy. Treatment period followed by 5 months post-enrollment monitoring.
primary endpoint:Change in long episode frequency during treatment period compared to pre-treatment baseline (Responder proportion, Percent Change)
claimed differentiation
Not specified in filing - no differentiation claims provided
language red flags
- Target and mechanism of action not disclosed in filing - significant information gap
- Phase 2 trial uses non-randomized, non-placebo-controlled design - unusual for efficacy claims
- No differentiation claims provided - limited competitive positioning information
- No stated risks explicitly acknowledged in available filing content
company-stated risks
- Not explicitly stated in filing - typical epilepsy drug risks (SUDEP, seizure worsening, cognitive effects) implied but not detailed
upcoming catalysts
- 2025-09-26Primary completion date